U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...
Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback